Bailee Hanover
Family · Owosso, MINPI 1518712421
Payments from drug & device makers
Across 81 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$279
- Lilly USA, LLC$218
- Biogen$209
- UCB, Inc.$71
- Eisai Inc.$68
- Genentech USA, Inc.$59
- plus $444 from 16 others
What the payments were for
- Food & beverage$1,349100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $279 |
| Lilly USA, LLC | 11 | $218 |
| Biogen | 10 | $209 |
| UCB, Inc. | 4 | $71 |
| Eisai Inc. | 2 | $68 |
| Genentech USA, Inc. | 3 | $59 |
| Amneal Pharmaceuticals LLC | 2 | $46 |
| Tanabe Pharma America, Inc. | 2 | $43 |
| Argenx US, Inc. | 2 | $43 |
| Pfizer | 2 | $39 |
| Aucta Pharmaceuticals, Inc. | 2 | $30 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| Merz Pharmaceuticals, LLC | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Catalyst Pharmaceuticals, Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $25 |
| SK Life Science, Inc. | 1 | $24 |
| Averitas Pharma Inc. | 1 | $22 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| OWP Pharmaceuticals, Inc. | 1 | $14 |
| AstraZeneca | 1 | $14 |
How this compares
$1,349 in reported general payments places this provider in the 75th percentile of 3,657 family providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 49 | $763 |
| RivastigmineRivastigmine Tartrate | 19 | $620 |
| Donepezil Hcl | 34 | $516 |
| Quetiapine Fumarate | 12 | $111 |
Paid to pharmacies, not to this prescriber.
Other family in Owosso
- Kylie KattelusOwosso$18K
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.